Antibody Screen, Identification, DAT, Elution, and Enhancement Methods
Key Takeaways
- A positive antibody screen is a signal to identify clinically significant unexpected antibodies before routine compatible red cell release.
- A negative autocontrol with a positive screen suggests an alloantibody; a positive autocontrol or positive DAT raises concern for autoantibody, drug effect, transfusion reaction, or in vivo coating.
- DAT detects red cells coated in vivo with IgG and/or complement; the antibody screen detects free antibody in patient plasma or serum.
- Elution is useful when antibody is bound to red cells, such as in hemolytic disease of the fetus and newborn or a delayed hemolytic transfusion reaction.
- Enhancement and enzyme methods change reaction strength, so the exam expects pattern recognition rather than memorized tube steps.
Screening versus identifying antibodies
An antibody screen uses reagent red cells to detect unexpected antibodies in patient plasma or serum. The screen answers a yes-or-no safety question: is there evidence of an antibody that could matter for transfusion or pregnancy? A positive screen is not the final answer. It triggers antibody identification, history review, and selection of compatible red cell units.
An antibody identification panel compares patient plasma against a larger set of reagent cells with known antigen profiles. The exam does not usually ask you to perform every bench step. It asks whether you can connect reaction patterns to likely specificities and safe unit selection.
| Finding | What it suggests | MLT decision pattern |
|---|---|---|
| Screen positive, autocontrol negative | Alloantibody is likely | Identify antibody and provide antigen-negative, crossmatch-compatible red cells |
| Screen positive, autocontrol positive | Autoantibody, recent transfusion, drug effect, or antibody coating patient cells | Check DAT and history; do not assume a simple alloantibody only |
| All panel cells reactive at AHG, autocontrol positive | Warm autoantibody pattern is possible | Consider adsorption workup by reference process and evaluate for underlying alloantibodies |
| Reaction only with antigen-positive cells | Specific alloantibody is likely | Confirm with rule-out and select antigen-negative units |
| Historical clinically significant antibody but current screen negative | Antibody may have evanesced | Honor history and issue antigen-negative units |
Clinically significant antibodies usually react at 37 C or the antiglobulin phase and can cause hemolytic transfusion reactions or hemolytic disease of the fetus and newborn. Rh, Kell, Kidd, Duffy, and S/s antibodies are high-yield. Lewis, P1, M, and cold autoantibodies are often less clinically significant when only cold-reactive, but exceptions and local policy matter.
Panel logic the exam rewards
Start with phase, strength, and autocontrol. Immediate-spin or room-temperature reactions suggest cold-reactive antibodies, ABO problems, or rouleaux. AHG-only reactions suggest IgG antibodies such as Rh, Kell, Kidd, Duffy, or S/s. A stronger reaction with homozygous antigen expression can reflect dosage, especially with Kidd, Duffy, MNS, and some Rh antibodies.
Then compare reactive cells to antigen profiles. If every K-positive cell reacts and every K-negative cell is nonreactive, anti-K is plausible. If an antibody screen is positive because of anti-Fya, the transfusion answer is Fy(a-) red cells, not merely ABO-compatible red cells.
Many programs teach a rule-of-three confirmation pattern: at least three antigen-positive cells react and at least three antigen-negative cells do not react. The exam point is not the arithmetic alone. The point is that an antibody should be supported by a defensible pattern, not by one convenient panel cell.
DAT and elution
The direct antiglobulin test (DAT) detects IgG and/or complement already attached to the patient's red cells in vivo. It is different from the antibody screen, which tests free antibody in plasma or serum.
| Test | Sample focus | High-yield use |
|---|---|---|
| Antibody screen | Patient plasma or serum plus reagent red cells | Finds unexpected free antibodies before transfusion |
| Autocontrol | Patient plasma or serum plus patient red cells | Helps separate alloantibody pattern from autoantibody or in vivo coating clues |
| DAT | Patient red cells plus antiglobulin reagent | Detects in vivo coating in HDFN, autoimmune hemolysis, drug-induced hemolysis, or transfusion reaction |
| Eluate testing | Antibody removed from coated patient red cells | Identifies antibody bound to cells in HDFN or delayed hemolytic transfusion reaction |
A positive DAT can be due to IgG, complement, or both. Anti-IgG positivity is common in warm autoimmune hemolytic anemia and many cases of HDFN. Complement-only positivity can be seen with cold-reactive processes. A post-transfusion patient with a new positive DAT and falling hemoglobin raises concern for a delayed hemolytic reaction, especially with Kidd antibodies, which are known for becoming undetectable and then returning after exposure.
Elution is most useful when the important antibody is stuck to red cells. In HDFN, an eluate from neonatal red cells can identify maternal IgG coating the infant cells. In a delayed hemolytic reaction, eluate testing can reveal the antibody coating transfused donor cells.
Enhancement and enzyme methods
Enhancement media and enzymes are tools for changing antibody-antigen reaction visibility. The MLT exam usually asks what pattern they create or which antibodies are affected.
| Method | High-yield effect | Exam caution |
|---|---|---|
| Low ionic strength solution (LISS) | Speeds IgG uptake and shortens incubation | Used for many routine antibody detection workflows |
| Polyethylene glycol (PEG) | Increases sensitivity for IgG antibodies | Can increase nonspecific reactivity; follow method limits |
| Albumin | Reduces zeta potential | Less sensitive than some modern methods but still a classic concept |
| Enzyme-treated cells | Enhance Rh, Kidd, Lewis, P1, and I reactivity | Destroy or weaken many Duffy and MNS antigens such as Fya, Fyb, M, and N |
| Thiol reagents such as dithiothreitol | Denature Kell system antigens and disrupt IgM | Useful in selected complex workups, such as daratumumab interference protocols by policy |
For exam decision-making, enzymes are a pattern amplifier. If a reaction disappears with enzyme-treated cells, think Duffy or MNS. If it becomes stronger, think Rh, Kidd, Lewis, P1, or I. Do not use an enzyme result in isolation; combine it with phase, autocontrol, patient history, and panel antigen profiles.
The safe transfusion answer
When a clinically significant antibody is identified, select red cell units negative for the corresponding antigen and compatible by the required crossmatch method. If specificity is unresolved and the transfusion is not emergent, routine release should wait. If the patient is bleeding and delay is dangerous, emergency-release documentation and physician authorization become part of the workflow.
A patient's antibody screen is positive at AHG. The autocontrol is negative. Panel cells that are K positive react, and K-negative cells are nonreactive. What is the best transfusion decision?
A newborn has a positive DAT. An eluate prepared from the infant's red cells reacts with D-positive reagent cells and not with D-negative cells. Which interpretation best fits?
Which findings support a clinically significant alloantibody that needs antigen-negative red cell selection? Select all that apply.
Select all that apply